J Mol Biol. 2019 Dec 27. pii: S0022-2836(19)30745-4. [Epub ahead of print]
Autophagy is a major, conserved cellular pathway by which cells deliver cytoplasmic contents to lysosomes for degradation. Genetic studies have revealed extensive links between autophagy and neurodegenerative disease, and disruptions to autophagy may contribute to pathology in some cases. Autophagy degrades many of the toxic, aggregate-prone proteins responsible for disease, including mutant huntingtin (mHTT), alpha-synuclein (α-syn), tau and others, raising the possibility that autophagy upregulation may help to reduce levels of toxic protein species and thereby alleviate disease. This review examines autophagy induction as a potential therapy in several neurodegenerative diseases - Alzheimer's disease, Parkinson's disease, polyglutamine diseases, and amyotrophic lateral sclerosis. Evidence in cells and in vivo demonstrates promising results in many disease models, in which autophagy upregulation is able to reduce the levels of toxic proteins, ameliorate signs of disease, and delay disease progression. However, effective therapeutic use of autophagy induction requires a detailed knowledge of how the disease affects the autophagy-lysosome pathway, as activating autophagy when the pathway cannot go to completion (e.g. when lysosomal degradation is impaired) may instead exacerbate disease in some cases. Investigating the interactions between autophagy and disease pathogenesis is thus a critical area for further research.
Keywords: Alzheimer’s disease; Parkinson’s disease; amyotrophic lateral sclerosis; lysosome; polyglutamine diseases